{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:12:20Z","timestamp":1780632740042,"version":"3.54.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82271658"],"award-info":[{"award-number":["82271658"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fujian Health Young and Middle-aged Scientific Research Major Project","award":["2021ZQNZD011"],"award-info":[{"award-number":["2021ZQNZD011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"DOI":"10.1186\/s40246-025-00741-w","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:09:18Z","timestamp":1742328558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Serine\/threonine kinase 11 (STK11) associated adnexal tumors: from biology to therapeutic impact"],"prefix":"10.1186","volume":"19","author":[{"given":"Guanxiang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"5","key":"741_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21(5):389\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"741_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"741_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"741_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","volume":"35","author":"C Stewart","year":"2019","unstructured":"Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151\u20136.","journal-title":"Semin Oncol Nurs"},{"issue":"9","key":"741_CR5","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/bjc.2011.394","volume":"105","author":"H Kajiyama","year":"2011","unstructured":"Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Nawa A, et al. Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. Br J Cancer. 2011;105(9):1288\u201394.","journal-title":"Br J Cancer"},{"issue":"1","key":"741_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s12885-018-4498-z","volume":"18","author":"JY Lee","year":"2018","unstructured":"Lee JY, Kim S, Kim YT, Lim MC, Lee B, Jung KW, et al. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. BMC Cancer. 2018;18(1):601.","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"741_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","volume":"155","author":"JS Berek","year":"2021","unstructured":"Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1):61\u201385.","journal-title":"Int J Gynaecol Obstet"},{"issue":"8","key":"741_CR8","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/jmedgenet-2021-108238","volume":"59","author":"D Grafodatskaya","year":"2022","unstructured":"Grafodatskaya D, O\u2019Rielly DD, Bedard K, Butcher DT, Howlett CJ, Lytwyn A, et al. Practice guidelines for BRCA1\/2 tumour testing in ovarian cancer. J Med Genet. 2022;59(8):727\u201336.","journal-title":"J Med Genet"},{"issue":"11","key":"741_CR9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s10038-022-01065-6","volume":"67","author":"L Yao","year":"2022","unstructured":"Yao L, Sun J, Hu L, Chen J, Zhang J, Xu Y, et al. Ovarian cancer risk of Chinese women with BRCA1\/2 germline pathogenic variants. J Hum Genet. 2022;67(11):639\u201342.","journal-title":"J Hum Genet"},{"key":"741_CR10","doi-asserted-by":"crossref","unstructured":"Angeli D, Salvi S, Tedaldi G. Genetic predisposition to breast and ovarian cancers: how many and which genes to test?? Int J Mol Sci 2020;21(3).","DOI":"10.3390\/ijms21031128"},{"issue":"3","key":"741_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020033451","volume":"30","author":"M Altamish","year":"2020","unstructured":"Altamish M, Dahiya R, Singh AK, Mishra A, Aljabali AAA, Satija S, et al. Role of the serine\/threonine kinase 11 (STK11) or liver kinase B1 (LKB1) gene in Peutz-Jeghers syndrome. Crit Rev Eukaryot Gene Expr. 2020;30(3):245\u201352.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"5","key":"741_CR12","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3892\/ol.2013.1527","volume":"6","author":"K Banno","year":"2013","unstructured":"Banno K, Kisu I, Yanokura M, Masuda K, Ueki A, Kobayashi Y, et al. Hereditary gynecological tumors associated with Peutz-Jeghers syndrome (Review). Oncol Lett. 2013;6(5):1184\u20138.","journal-title":"Oncol Lett"},{"key":"741_CR13","doi-asserted-by":"crossref","unstructured":"Piombino C, Cortesi L, Lambertini M, Punie K, Grandi G, Toss A. Secondary Prevention in Hereditary Breast and\/or Ovarian Cancer Syndromes Other Than BRCA. J. Oncol. 2020;2020:6384190.","DOI":"10.1155\/2020\/6384190"},{"key":"741_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.semcdb.2016.02.015","volume":"52","author":"BY Shorning","year":"2016","unstructured":"Shorning BY, Clarke AR. Energy sensing and cancer: LKB1 function and lessons learnt from Peutz-Jeghers syndrome. Semin Cell Dev Biol. 2016;52:21\u20139.","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"741_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/01.LAB.0000049821.16698.D0","volume":"83","author":"C Kuragaki","year":"2003","unstructured":"Kuragaki C, Enomoto T, Ueno Y, Sun H, Fujita M, Nakashima R, et al. Mutations in the STK11 gene characterize minimal deviation adenocarcinoma of the uterine cervix. Lab Invest. 2003;83(1):35\u201345.","journal-title":"Lab Invest"},{"issue":"6","key":"741_CR16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"741_CR17","first-page":"375","volume":"15","author":"M Stasenko","year":"2019","unstructured":"Stasenko M, Fillipova O, Tew WP. Fallopian Tube Carcinoma J Oncol Pract. 2019;15(7):375\u201382.","journal-title":"Fallopian Tube Carcinoma J Oncol Pract"},{"issue":"4","key":"741_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00404-016-4035-8","volume":"293","author":"I Meinhold-Heerlein","year":"2016","unstructured":"Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, et al. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet. 2016;293(4):695\u2013700.","journal-title":"Arch Gynecol Obstet"},{"issue":"5","key":"741_CR19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00404-014-3364-8","volume":"290","author":"F Zeppernick","year":"2014","unstructured":"Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet. 2014;290(5):839\u201342.","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"741_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3802\/jgo.2015.26.2.87","volume":"26","author":"J Prat","year":"2015","unstructured":"Prat J. FIGO\u2019s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26(2):87\u20139.","journal-title":"J Gynecol Oncol"},{"issue":"5","key":"741_CR21","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.21873\/invivo.12980","volume":"36","author":"A Matsuoka","year":"2022","unstructured":"Matsuoka A, Tate S, Nishikimi K, Iwamoto M, Otsuka S, Shozu M. Validity of the 2014 FIGO stage IIIA1 subclassification for ovarian, fallopian tube, and peritoneal cancers. Vivo. 2022;36(5):2453\u201360.","journal-title":"Vivo"},{"key":"741_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-0716-1956-8_1","volume":"2424","author":"AS O\u2019Shea","year":"2022","unstructured":"O\u2019Shea AS. Clinical staging of ovarian cancer. Methods Mol Biol. 2022;2424:3\u201310.","journal-title":"Methods Mol Biol"},{"key":"741_CR23","doi-asserted-by":"crossref","unstructured":"M\u00e9tairie M, Benoit L, Koual M, Bentivegna E, Wohrer H, Bolze PA et al. A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer. Cancers. 2023;15(3).","DOI":"10.3390\/cancers15030706"},{"issue":"suppl8","key":"741_CR24","doi-asserted-by":"publisher","first-page":"viii8","DOI":"10.1093\/annonc\/mdx445","volume":"28","author":"LR Duska","year":"2017","unstructured":"Duska LR, Kohn EC. The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. Ann Oncol. 2017;28(suppl8):viii8\u201312.","journal-title":"Ann Oncol"},{"issue":"8","key":"741_CR25","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1097\/IGC.0000000000001331","volume":"28","author":"M Gomes Ferreira","year":"2018","unstructured":"Gomes Ferreira M, Sancho de Salas M, Gonz\u00e1lez Sarmiento R, Doyague S\u00e1nchez MJ. Changes in the management and prognosis of ovarian cancer due to the new FIGO and WHO classifications: A case series observational descriptive study. Seven years of Follow-up. Int J Gynecol Cancer. 2018;28(8):1461\u201370.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"741_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: A review. Cancer Biol Med. 2017;14(1):9\u201332.","journal-title":"Cancer Biol Med"},{"key":"741_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/path.1000","volume":"195","author":"JM Piek","year":"2001","unstructured":"Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451\u20136.","journal-title":"J Pathol"},{"issue":"1","key":"741_CR28","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","volume":"8","author":"SI Labidi-Galy","year":"2017","unstructured":"Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8(1):1093.","journal-title":"Nat Commun"},{"issue":"23","key":"741_CR29","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA"},{"issue":"3","key":"741_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ygyno.2010.05.011","volume":"118","author":"D Vicus","year":"2010","unstructured":"Vicus D, Finch A, Cass I, Rosen B, Murphy J, Fan I, et al. Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube. Gynecol Oncol. 2010;118(3):299\u2013302.","journal-title":"Gynecol Oncol"},{"issue":"26","key":"741_CR31","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM194912292412601","volume":"241","author":"H Jeghers","year":"1949","unstructured":"Jeghers H, Mc KV, Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. N Engl J Med. 1949;241(26):1031\u20136.","journal-title":"N Engl J Med"},{"issue":"1","key":"741_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/PAP.0000000000000460","volume":"32","author":"JA Bennett","year":"2025","unstructured":"Bennett JA, Oliva E. STK11 adnexal tumor: exploring the association with Peutz-Jeghers syndrome and its distinction from morphologic mimickers. Adv Anat Pathol. 2025;32(1):98\u2013108.","journal-title":"Adv Anat Pathol"},{"issue":"2","key":"741_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4132\/jptm.2016.07.01","volume":"51","author":"EN Kim","year":"2017","unstructured":"Kim EN, Kim GH, Kim J, Park IA, Shin JH, Chai Y, et al. A pyloric Gland-Phenotype ovarian mucinous tumor resembling lobular endocervical glandular hyperplasia in a patient with Peutz-Jeghers syndrome. J Pathol Transl Med. 2017;51(2):159\u201364.","journal-title":"J Pathol Transl Med"},{"key":"741_CR34","doi-asserted-by":"publisher","first-page":"1094839","DOI":"10.3389\/fmed.2023.1094839","volume":"10","author":"X Li","year":"2023","unstructured":"Li X, Qi Y, Zhang W, Rao Y, Zhang N, Qu P. Peutz-Jeghers syndrome with gastric-type mucinous endocervical adenocarcinoma and sex-cord tumor with annular tubules: A case report. Front Med (Lausanne). 2023;10:1094839.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"741_CR35","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/PAS.0000000000001677","volume":"45","author":"JA Bennett","year":"2021","unstructured":"Bennett JA, Young RH, Howitt BE, Croce S, Wanjari P, Zhen C, et al. A distinctive adnexal (Usually Paratubal) neoplasm often associated with Peutz-Jeghers syndrome and characterized by STK11 alterations (STK11 adnexal Tumor): A Report of 22 Cases. Am J Surg Pathol. 2021;45(8):1061\u201374.","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"741_CR36","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1158\/2159-8290.CD-18-1261","volume":"9","author":"PE Hollstein","year":"2019","unstructured":"Hollstein PE, Eichner LJ, Brun SN, Kamireddy A, Svensson RU, Vera LI, et al. The AMPK-Related kinases SIK1 and SIK3 mediate key Tumor-Suppressive effects of LKB1 in NSCLC. Cancer Discov. 2019;9(11):1606\u201327.","journal-title":"Cancer Discov"},{"issue":"6","key":"741_CR37","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.1007\/s13277-015-4639-9","volume":"37","author":"NS Li","year":"2016","unstructured":"Li NS, Zou JR, Lin H, Ke R, He XL, Xiao L, et al. LKB1\/AMPK inhibits TGF-\u03b21 production and the TGF-\u03b2 signaling pathway in breast cancer cells. Tumour Biol. 2016;37(6):8249\u201358.","journal-title":"Tumour Biol"},{"issue":"1","key":"741_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12881-018-0626-5","volume":"19","author":"YL Jiang","year":"2018","unstructured":"Jiang YL, Zhao ZY, Li BR, Yang F, Li J, Jin XW, et al. The altered activity of P53 signaling pathway by STK11 gene mutations and its cancer phenotype in Peutz-Jeghers syndrome. BMC Med Genet. 2018;19(1):141.","journal-title":"BMC Med Genet"},{"issue":"17","key":"741_CR39","doi-asserted-by":"publisher","first-page":"10064","DOI":"10.3390\/ijms231710064","volume":"23","author":"T Shimada","year":"2022","unstructured":"Shimada T, Yabuki Y, Noguchi T, Tsuchida M, Komatsu R, Hamano S, et al. The distinct roles of LKB1 and AMPK in p53-Dependent apoptosis induced by cisplatin. Int J Mol Sci. 2022;23(17):10064.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"741_CR40","first-page":"1140","volume":"58","author":"JY Lee","year":"1998","unstructured":"Lee JY, Dong SM, Kim HS, Kim SY, Na EY, Shin MS, et al. A distinct region of chromosome 19p13.3 associated with the sporadic form of adenoma malignum of the uterine cervix. Cancer Res. 1998;58(6):1140\u20133.","journal-title":"Cancer Res"},{"issue":"2","key":"741_CR41","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.lungcan.2013.04.013","volume":"81","author":"SM Lee","year":"2013","unstructured":"Lee SM, Choi JE, Na YK, Lee EJ, Lee WK, Choi YY, et al. Genetic and epigenetic alterations of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean Non-Small cell lung cancers. Lung Cancer. 2013;81(2):194\u20139.","journal-title":"Lung Cancer"},{"key":"741_CR42","doi-asserted-by":"publisher","first-page":"1449543","DOI":"10.3389\/fcell.2024.1449543","volume":"12","author":"J Kang","year":"2024","unstructured":"Kang J, Gallucci S, Pan J, Oakhill JS, Sanij E. The role of STK11\/LKB1 in cancer biology: implications for ovarian tumorigenesis and progression. Front Cell Dev Biol. 2024;12:1449543.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"741_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13048-023-01234-x","volume":"16","author":"AW Adamson","year":"2023","unstructured":"Adamson AW, Ding YC, Steele L, Leong LA, Morgan R, Wakabayashi MT, et al. Genomic analyses of germline and somatic variation in High-Grade serous ovarian cancer. J Ovarian Res. 2023;16(1):141.","journal-title":"J Ovarian Res"},{"key":"741_CR44","doi-asserted-by":"crossref","unstructured":"Rebuzzi F, Ulivi P, Tedaldi G. Genetic predisposition to colorectal cancer: how many and which genes to test?? Int J Mol Sci 2023;24(3).","DOI":"10.3390\/ijms24032137"},{"issue":"1","key":"741_CR45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.21037\/tlcr-22-530","volume":"12","author":"TE Stinchcombe","year":"2023","unstructured":"Stinchcombe TE. Narrative review: blood and tumor biomarker testing in Non-Small cell lung cancer without an oncogenic driver. Transl Lung Cancer Res. 2023;12(1):158\u201367.","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"741_CR46","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1245\/s10434-022-12829-x","volume":"30","author":"S Hosseini","year":"2023","unstructured":"Hosseini S, Acar A, Sen M, Meeder K, Singh P, Yin K, et al. Penetrance of gastric adenocarcinoma susceptibility genes: A systematic review. Ann Surg Oncol. 2023;30(3):1795\u2013807.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"741_CR47","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/j.1349-7006.1999.tb00793.x","volume":"90","author":"Y Nishioka","year":"1999","unstructured":"Nishioka Y, Kobayashi K, Sagae S, Sugimura M, Ishioka S, Nagata M, et al. Mutational analysis of STK11 gene in ovarian carcinomas. Jpn J Cancer Res. 1999;90(6):629\u201332.","journal-title":"Jpn J Cancer Res"},{"issue":"1","key":"741_CR48","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0002-9440(10)64735-9","volume":"156","author":"DC Connolly","year":"2000","unstructured":"Connolly DC, Katabuchi H, Cliby WA, Cho KR. Somatic mutations in the STK11\/LKB1 gene are uncommon in rare gynecological tumor types associated with Peutz-Jegher\u2019s syndrome. Am J Pathol. 2000;156(1):339\u201345.","journal-title":"Am J Pathol"},{"issue":"10","key":"741_CR49","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00431-006-0352-4","volume":"166","author":"G Massa","year":"2007","unstructured":"Massa G, Roggen N, Renard M, Gille JJ. Germline mutation in the STK11 gene in a Girl with an ovarian Sertoli cell tumour. Eur J Pediatr. 2007;166(10):1083\u20135.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"741_CR50","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/pbc.22433","volume":"55","author":"L Howell","year":"2010","unstructured":"Howell L, Bader A, Mullassery D, Losty P, Auth M, Kokai G. Sertoli Leydig cell ovarian tumour and gastric polyps as presenting features of Peutz-Jeghers syndrome. Pediatr Blood Cancer. 2010;55(1):206\u20137.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"741_CR51","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/jog.15107","volume":"48","author":"OS Yucel Cicek","year":"2022","unstructured":"Yucel Cicek OS, Gezer S, Cakir O, Hekimoglu Gurbuz R. Extremely high Anti-Mullerian hormone levels detected during infertility workup revealing sex cord tumor with annular tubules and underlying Peutz-Jeghers syndrome: A case report. J Obstet Gynaecol Res. 2022;48(2):492\u20136.","journal-title":"J Obstet Gynaecol Res"},{"issue":"1","key":"741_CR52","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3802\/jgo.2013.24.1.92","volume":"24","author":"SY Kwon","year":"2013","unstructured":"Kwon SY, Choe MS, Lee HW, Lee HJ, Shin SJ, Cho CH. Minimal deviation adenocarcinoma of the cervix and tumorlets of Sex-Cord stromal tumor with annular tubules of the ovary in Peutz-Jeghers syndrome. J Gynecol Oncol. 2013;24(1):92\u20135.","journal-title":"J Gynecol Oncol"},{"key":"741_CR53","doi-asserted-by":"publisher","first-page":"101673","DOI":"10.1016\/j.gore.2024.101673","volume":"57","author":"T Ichinose","year":"2025","unstructured":"Ichinose T, Takasaki K, Takahashi Y, Hirano M, Nishida H, Hiraike H, et al. Lobular endocervical glandular hyperplasia diagnosed during surveillance for Peutz-Jeghers syndrome: A case report. Gynecol Oncol Rep. 2025;57:101673.","journal-title":"Gynecol Oncol Rep"},{"issue":"8","key":"741_CR54","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.prp.2018.06.009","volume":"214","author":"YJ Choi","year":"2018","unstructured":"Choi YJ, Ho J, Lee A, Hur SY, Park HC, Park JS, et al. Disparate genomic characteristics of concurrent endometrial adenocarcinoma and ovarian granulosa cell tumor, revealed by targeted Next-Generation sequencing. Pathol Res Pract. 2018;214(8):1231\u20133.","journal-title":"Pathol Res Pract"},{"issue":"3","key":"741_CR55","first-page":"247","volume":"35","author":"A Neyaz","year":"2019","unstructured":"Neyaz A, Husain N, Deodhar M, Khurana R, Shukla S, Arora A. Synchronous cervical minimal deviation adenocarcinoma, gastric type adenocarcinoma and lobular endocervical glandular hyperplasia along with STIL in Peutz-Jeghers syndrome: eliciting oncogenesis pathways. Turk Patoloji Derg. 2019;35(3):247\u201353.","journal-title":"Turk Patoloji Derg"},{"key":"741_CR56","doi-asserted-by":"crossref","unstructured":"Feng YY, Li Z, Zhang MH. Bilateral Peutz-Jeghers-Associated sex cord tumor with annular tubules combined with unilateral adult granulosa cell tumor: a case report. Pathol Res Pract. 2023;31(7):1352\u20138.","DOI":"10.1177\/10668969221146744"},{"issue":"4","key":"741_CR57","doi-asserted-by":"publisher","first-page":"380","DOI":"10.6004\/jnccn.2020.0017","volume":"18","author":"MB Daly","year":"2020","unstructured":"Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, et al. NCCN guidelines insights: Genetic\/Familial High-Risk assessment: breast, ovarian, and pancreatic, version 1.2020. J Natl Compr Canc Netw. 2020;18(4):380\u201391.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"741_CR58","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/ajg.2014.435","volume":"110","author":"S Syngal","year":"2015","unstructured":"Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: genetic testing and management of hereditary Gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223\u201362. quiz e263.","journal-title":"Am J Gastroenterol"},{"key":"741_CR59","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2018.09.004","volume":"104","author":"DB Vangala","year":"2018","unstructured":"Vangala DB, Cauchin E, Balma\u00f1a J, Wyrwicz L, van Cutsem E, G\u00fcller U, et al. Screening and surveillance in hereditary Gastrointestinal cancers: recommendations from the European society of digestive oncology (ESDO) expert discussion at the 20th European society for medical oncology (ESMO)\/World Congress on Gastrointestinal cancer, Barcelona, June 2018. Eur J Cancer. 2018;104:91\u2013103.","journal-title":"Eur J Cancer"},{"issue":"20","key":"741_CR60","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1158\/1078-0432.CCR-22-0568","volume":"28","author":"V Serra","year":"2022","unstructured":"Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, et al. Identification of a Molecularly-Defined subset of breast and ovarian cancer models that respond to WEE1 or ATR Inhibition, overcoming PARP inhibitor resistance. Clin Cancer Res. 2022;28(20):4536\u201350.","journal-title":"Clin Cancer Res"},{"key":"741_CR61","doi-asserted-by":"crossref","unstructured":"George SHL, Donenberg T, Alexis C, DeGennaro V Jr., Dyer H, Yin S et al. Gene sequencing for pathogenic variants among adults with breast and ovarian cancer in the Caribbean. JAMA Netw Open 2021;4(3):e210307.","DOI":"10.1001\/jamanetworkopen.2021.0307"},{"issue":"5","key":"741_CR62","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"15","key":"741_CR63","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.20.02785","volume":"39","author":"AW Kurian","year":"2021","unstructured":"Kurian AW, Ward KC, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, et al. Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012\u20132019. J Clin Oncol. 2021;39(15):1631\u201340.","journal-title":"J Clin Oncol"},{"issue":"3","key":"741_CR64","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/MOG.0000000000000718","volume":"37","author":"I Tacheci","year":"2021","unstructured":"Tacheci I, Kopacova M, Bures J. Peutz-Jeghers syndrome. Curr Opin Gastroenterol. 2021;37(3):245\u201354.","journal-title":"Curr Opin Gastroenterol"},{"key":"741_CR65","doi-asserted-by":"crossref","unstructured":"Watanabe T, Soeda S, Endo Y, Okabe C, Sato T, Kamo N et al. Rare hereditary gynecological cancer syndromes. Int J Mol Sci. 2022;23(3).","DOI":"10.3390\/ijms23031563"},{"issue":"4","key":"741_CR66","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s41379-019-0375-9","volume":"33","author":"JA Bennett","year":"2020","unstructured":"Bennett JA, Ritterhouse LL, Furtado LV, Lastra RR, Pesci A, Newell JM, et al. Female adnexal tumors of probable wolffian origin: morphological, immunohistochemical, and molecular analysis of 15 cases. Mod Pathol. 2020;33(4):734\u201347.","journal-title":"Mod Pathol"},{"issue":"2","key":"741_CR67","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/ijgc-2020-002018","volume":"31","author":"R Al Harbi","year":"2021","unstructured":"Al Harbi R, McNeish IA, El-Bahrawy M. Ovarian sex cord-stromal tumors: an update on clinical features, molecular changes, and management. Int J Gynecol Cancer. 2021;31(2):161\u20138.","journal-title":"Int J Gynecol Cancer"},{"key":"741_CR68","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12885-015-1277-y","volume":"15","author":"Q Qian","year":"2015","unstructured":"Qian Q, You Y, Yang J, Cao D, Zhu Z, Wu M, et al. Management and prognosis of patients with ovarian sex cord tumor with annular tubules: a retrospective study. BMC Cancer. 2015;15:270.","journal-title":"BMC Cancer"},{"issue":"1","key":"741_CR69","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.pathol.2017.09.007","volume":"50","author":"RH Young","year":"2018","unstructured":"Young RH. Ovarian sex Cord-Stromal tumours and their mimics. Pathology. 2018;50(1):5\u201315.","journal-title":"Pathology"},{"key":"741_CR70","unstructured":"NCCN Guidelines Version. 1. 2023 Ovarian cancer\/fallopian tube cancer\/Primary Peritoneal Cancer. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1453"},{"issue":"15","key":"741_CR71","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","volume":"32","author":"AP Finch","year":"2014","unstructured":"Finch AP, Lubinski J, M\u00f8ller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547\u201353.","journal-title":"J Clin Oncol"},{"key":"741_CR72","doi-asserted-by":"crossref","unstructured":"Irelli A, Patruno LV, Chiatamone Ranieri S, Di Giacomo D, Malatesta S, Alesse E et al. Role of breast cancer risk Estimation models to identify women eligible for genetic testing and risk-Reducing surgery. Biomedicines. 2024;12(4).","DOI":"10.3390\/biomedicines12040714"},{"issue":"8","key":"741_CR73","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","volume":"26","author":"ND Kauff","year":"2008","unstructured":"Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331\u20137.","journal-title":"J Clin Oncol"},{"issue":"Supplementum2","key":"741_CR74","first-page":"6","volume":"32","author":"L Foretov\u00e1","year":"2019","unstructured":"Foretov\u00e1 L, Navr\u00e1tilov\u00e1 M, Svoboda M, Va\u0161\u00ed\u010dkov\u00e1 P, S\u0165ahlov\u00e1 EH, H\u00e1zov\u00e1 J, et al. Recommendations for preventive care for women with rare genetic cause of breast and ovarian cancer. Klin Onkol. 2019;32(Supplementum2):6\u201313.","journal-title":"Klin Onkol"},{"key":"741_CR75","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","volume":"132","author":"C Marchetti","year":"2018","unstructured":"Marchetti C, De Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, et al. Hormone replacement therapy after prophylactic risk-Reducing Salpingo-Oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A Meta-Analysis. Crit Rev Oncol Hematol. 2018;132:111\u20135.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"741_CR76","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","volume":"153","author":"S Gordhandas","year":"2019","unstructured":"Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM. Hormone replacement therapy after risk reducing Salpingo-Oophorectomy in patients with BRCA1 or BRCA2 mutations; A systematic review of risks and benefits. Gynecol Oncol. 2019;153(1):192\u2013200.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"741_CR77","doi-asserted-by":"publisher","first-page":"407","DOI":"10.17219\/acem\/90767","volume":"28","author":"I Nowak-Psiorz","year":"2019","unstructured":"Nowak-Psiorz I, Cie\u0107wie\u017c SM, Brodowska A, Starczewski A. Treatment of ovarian endometrial cysts in the context of recurrence and fertility. Adv Clin Exp Med. 2019;28(3):407\u201313.","journal-title":"Adv Clin Exp Med"},{"key":"741_CR78","doi-asserted-by":"crossref","unstructured":"Loboda AP, Adonin LS, Zvereva SD, Guschin DY, Korneenko TV, Telegina AV et al. BRCA Mutations-The Achilles heel of breast, ovarian and other epithelial cancers. Int J Mol Sci 2023;24(5).","DOI":"10.3390\/ijms24054982"},{"issue":"5","key":"741_CR79","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1503523","volume":"374","author":"LC Hartmann","year":"2016","unstructured":"Hartmann LC, Lindor NM. The role of Risk-Reducing surgery in hereditary breast and ovarian cancer. N Engl J Med. 2016;374(5):454\u201368.","journal-title":"N Engl J Med"},{"issue":"1","key":"741_CR80","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ygyno.2022.07.029","volume":"167","author":"KM Moss","year":"2022","unstructured":"Moss KM, Mishra GD, Krejany EO, Hickey M. What happens after menopause?? (WHAM): A prospective controlled study of symptom profiles up to 12 months after Pre-Menopausal Risk-Reducing Salpingo-Oophorectomy. Gynecol Oncol. 2022;167(1):58\u201364.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"741_CR81","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.3390\/curroncol30020185","volume":"30","author":"AC Alves-Nogueira","year":"2023","unstructured":"Alves-Nogueira AC, Melo D, Carona C, Figueiredo-Dias M. The psychosocial impact of the decision to undergo Risk-Reducing Salpingo-Oophorectomy surgery in BRCA mutation carriers and the role of Physician-Patient communication. Curr Oncol. 2023;30(2):2429\u201340.","journal-title":"Curr Oncol"},{"issue":"3","key":"741_CR82","doi-asserted-by":"publisher","first-page":"300060521996563","DOI":"10.1177\/0300060521996563","volume":"49","author":"C Li","year":"2021","unstructured":"Li C, Aishajiang R, Teng Y, Xu T, Ding L, Dong L. Non-Peutz-Jeghers syndrome-associated ovarian sex cord tumor with annular tubules treated by radiotherapy: a case report and literature review. J Int Med Res. 2021;49(3):300060521996563.","journal-title":"J Int Med Res"},{"key":"741_CR83","doi-asserted-by":"crossref","unstructured":"West HJ, McCleland M, Cappuzzo F, Reck M, Mok TS, Jotte RM et al. Clinical efficacy of Atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial. J Immunother Cancer. 2022;10(2).","DOI":"10.1136\/jitc-2021-003027"},{"issue":"25","key":"741_CR84","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371\u201381.","journal-title":"N Engl J Med"},{"key":"741_CR85","doi-asserted-by":"crossref","unstructured":"Henick BS, Koch PD, Gainor JF, Awad MM, Chiuzan C, Izard S et al. Neoadjuvant atezolizumab\u2009+\u2009chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. J Immunother Cancer. 2024;12(12).","DOI":"10.1136\/jitc-2024-009301"},{"issue":"1","key":"741_CR86","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jtho.2024.09.1381","volume":"20","author":"S Peters","year":"2025","unstructured":"Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab with or without Tremelimumab in combination with chemotherapy in First-Line metastatic NSCLC: Five-Year overall survival outcomes from the phase 3 POSEIDON trial. J Thorac Oncol. 2025;20(1):76\u201393.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"741_CR87","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/03008916231204441","volume":"110","author":"A Olsen","year":"2024","unstructured":"Olsen A, Lebedeva A, Nosova P, Nikulin V, Sharova M, Ignatova E, et al. Impact of the STK11\/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort. Tumori. 2024;110(2):146\u201352.","journal-title":"Tumori"},{"key":"741_CR88","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejca.2021.01.050","volume":"148","author":"N Krishnamurthy","year":"2021","unstructured":"Krishnamurthy N, Goodman AM, Barkauskas DA, Kurzrock R. STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. Eur J Cancer. 2021;148:215\u201329.","journal-title":"Eur J Cancer"},{"issue":"3","key":"741_CR89","doi-asserted-by":"publisher","first-page":"317","DOI":"10.18597\/rcog.3888","volume":"73","author":"FR Ruiz-Echeverr\u00eda","year":"2022","unstructured":"Ruiz-Echeverr\u00eda FR, Beltr\u00e1n-Salazar MI, Calder\u00f3n-Quiroz PH, Lalinde-Trivi\u00f1o JD, Palencia-Palacios M, Suesc\u00fan-Garay O. Ovarian sex cord tumor with annular tubules: case report and review of the literature. Rev Colomb Obstet Ginecol. 2022;73(3):317\u201329.","journal-title":"Rev Colomb Obstet Ginecol"}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-025-00741-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40246-025-00741-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-025-00741-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:54:16Z","timestamp":1742331256000},"score":1,"resource":{"primary":{"URL":"https:\/\/humgenomics.biomedcentral.com\/articles\/10.1186\/s40246-025-00741-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["741"],"URL":"https:\/\/doi.org\/10.1186\/s40246-025-00741-w","relation":{},"ISSN":["1479-7364"],"issn-type":[{"value":"1479-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors reviewed the article and agreed to submit the manuscript to this journal for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}